stockrowDefinium Therapeutics, Inc.
DFTX Healthcare Biotechnology
- EPS
- −188.0%
- Free cash flow
- −78.3%
- Total debt
- −11.5%
Quarter to June 2026, against a year earlier
Follow DFTX
Alert me
Definium Therapeutics, Inc. (DFTX) Return on assets
Definium Therapeutics, Inc.'s return on assets over the twelve months to 30 June 2026 was −51.4%, down 1.8 percentage points from fiscal 2025 (−49.5%). Over the past ten years it has ranged from −1,306.5% (fiscal 2017) to −7.90% (fiscal 2016); the current reading is higher than 70% of that period. That is below the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −49.5% | 1.42 |
| FY2024 | −50.9% | 14.07 |
| FY2023 | −65.0% | (31.00) |
| FY2022 | −34.0% | 41.78 |
| FY2021 | −75.8% | 4.90 |
| FY2020 | −80.7% | 743.01 |
| FY2019 | −823.7% | (777.79) |
| FY2018 | −45.9% | 1,260.63 |
| FY2017 | −1,306.5% | (1,298.64) |
| FY2016 | −7.90% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ARQT Arcutis Biotherapeutics, Inc. compare | 6.68% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −5.32% |
| ABCL AbCellera Biologics Inc. compare | −12.2% |
| TNGX Tango Therapeutics, Inc. compare | −18.9% |
| DNTH Dianthus Therapeutics, Inc. compare | −21.8% |
| IOVA Iovance Biotherapeutics, Inc. compare | −23.3% |
| RLAY Relay Therapeutics, Inc. compare | −33.7% |
| EWTX Edgewise Therapeutics, Inc. compare | −36.1% |
| DFTX Definium Therapeutics, Inc. | −51.4% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)